Top of this page
Skip navigation, go straight to the content

Welcome to the UCB U.S. Newsroom

Our communications team aims to serve the media with timely,  valuable and reliable information. This section offers resources for  journalists, editors and other media professionals.


image description

Contact Us

For general media related enquiries, please contact us at:

UCB in the U.S.

image description
  • UCB entered the U.S. marketplace in 1994 through the acquisition of Whitby Pharmaceuticals and Northampton Medical, Inc.
  • In 1996, UCB launched Zyrtec® (cetirizine HCl) in co-promotion with Pfizer. In 1999, a New Drug Application was submitted and approved for Keppra® (levetiracetam) tablets as adjunctive therapy for adults with partial onset seizures.
  • UCB acquired Celltech Pharmaceuticals in June 2004. UCB also acquired majority shares of Schwarz Pharma AG in December 2006, further enriching the UCB product portfolio and pipeline and making it the world’s fifth-largest biopharmaceutical company.
  • In 2008, Cimzia® (certolizumab pegol), the first biologic product for UCB, became commercially available in the U.S.
  • UCB accelerated its U.S. transition to a purely specialty-focused biopharmaceutical company and exited the primary care market in 2010 as part of the company’s long-term strategy to focus on immunology and neurology.


  • [{"href":"#","title":" ","src":"../_up/ucb_usa_com/images/UCB_Logo_and_Tagline_cropped.jpg"},{"href":"#","title":" ","src":"../_up/ucb_usa_com/images/Smyrna_Campus.jpg"},{"href":"#","title":" ","src":"../_up/ucb_usa_com/images/Arthritis_Foundation_Team_at_the_Campus_5K.JPG"},{"href":"#","title":" ","src":"../_up/ucb_usa_com/images/Parkinsons_Foundation_Team_at_the_Campus_5K.JPG"},{"href":"#","title":" ","src":"../_up/ucb_usa_com/images/Starting_Line_at_the_Annual_Run_for_Their_Lives_5K.JPG"}]


Inspired by patients. Driven by science